Skip to main content
. 2012 Jan 3;30(4):387–393. doi: 10.1200/JCO.2010.33.3369

Fig 1.

Fig 1.

Overall experimental design of (A) group A therapy, (B) group B therapy, (C) group C therapy for CNS-positive patients, (D) group C therapy for CNS-negative patients. The number after the regimen name indicates the cycle number. ADR, doxorubicin; ARA C, cytarabine; COP, cyclophosphamide, vincristine, and prednisone; COPAD, cyclophosphamide, vincristine, prednisone, and doxorubicin; COPADM, COPAD with high-dose methotrexate (HD-MTX; 8 g/m2); CPM, cyclophosphamide; CYM, cytarabine and HD-MTX; CYVE, cytarabine 2 g/m2 and etoposide 100 mg/m2; IT, intrathecal; M1, maintenance cycle 1; M2, maintenance cycle 2; M3, maintenance cycle 3; M4, maintenance cycle 4; VP-16, etoposide.